Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers ...
How have -- I know you just set up the payer team, but how have initial payer discussions been going for pembrolizumab and SMA ... and we're going to continue to do our work and we'll continue to ...
Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data ...
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...
News Medical on MSN16h
New treatment combination improves outcomes for small cell bladder and prostate cancer patientsA research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...
SurvivorNet on MSN1d
New CML Approval: Leading Leukemia Expert on the ‘Significant Improvement’ Asciminib (Scemblix) Offers Patients as a First-Line Treatment OptionFor chronic myeloid leukemia (CML) patients, there is a promising new first-line drug approval with asciminib (brand name ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback